Perrigo announces first-to-file patent challenge
DUBLIN — Perrigo on Wednesday announced that it has filed an abbreviated new drug application with the Food and Drug Administration for desoximetasone topical spray 0.25%. The company also has notified Taro Pharmaceuticals U.S.A., the owner of the reference listed drug, of the filing.
Taro filed suit against Perrigo on July 28, claiming patent infringement. Perrigo believes it is first to file, which entitles it to a period of generic exclusivity.
"This filing highlights our continued investment in new products and dedication to bringing topicals to market. Perrigo is committed to making quality health care more affordable for consumers around the globe," said Joseph C. Papa, Perrigo's chairman, president and CEO.
Topicort is used for the treatment of plaque psoriasis in patients 18 years of age or older. The drug had annual sales of $29 million, according to Symphony Health Solutions.
IRI: 15% of consumers looking to increase purchase of premium-positioned natural, organic products in next year
McKesson extends pharmaceutical distribution deal with CVS Caremark
SAN FRANCISCO — McKesson announced on Wednesday a three-year extension of its existing distribution agreement with CVS Caremark through June 2019.
“We have a long track record of delivering comprehensive supply chain solutions to CVS Caremark which in turn allows CVS Caremark to ensure the highest level of pharmaceutical care to its customers,” stated Paul Julian, EVP, group president, McKesson. “We are pleased to have extended our agreement with CVS Caremark and continue our long standing partnership.”